5Fisher RI,Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemrtherapy regimens for advanced non Hodgkin's lymphoma[J]. N Engl J Med,1993,328:1 002-1 006.
6Shipp MA, Neuberg D, Janicek M, et al. High-dose CHOP as initial therapy for Patients with poorprognosis aggressive non-Hodgkin's lymphoma dose-finding pilot study[J]. J Clin Oncol,1995,13..2 916-2 923.
7Bartlett NL, Petroni GR, Parker BA, et al. Dose-escalated cyclophosphamide Doxorubicin, bincristine, predni-sone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854 [J]. Cancer, 2001,92 (2) :207-217.
8Itoh K, Ohtsu T, Fukuda H,et al. Randomized phase Ⅱ study of biweekly CHOP and dose-escalated CHOP21 with prophylactic use of lenograstim (glycosylated GCSF) in aggressive non-Hodgkin' s lymphoma. Japan Clinical Oncology Group Study 9505 [J]. Ann Oncol, 2002,13:1 347-1 355.
9Norton L. Evolving concepts in the systemic drug therapy of bresst cancer[J]. Semin Oncol, 1997,24 (Suppl 10) :S10-3- S10-10.
10Gregory SA, Case DC, Bosserman L, et al. Four teenday CHOP supported with Granulocyte colonystimulating factor in patients with aggressive non Hodgkin's lymphoma results of a phase Ⅱ study[J]. Clin Lymphoma, 2003, 4:93-98.
